FY2024 Earnings Estimate for Genelux Issued By HC Wainwright

Genelux Co. (NASDAQ:GNLX) – Research analysts at HC Wainwright boosted their FY2024 EPS estimates for Genelux in a report released on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.84) per share for the year, up from their prior forecast of ($0.88). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.07) EPS and FY2028 earnings at $1.23 EPS.

Genelux Stock Down 5.3 %

Shares of NASDAQ:GNLX opened at $3.03 on Thursday. The firm has a fifty day simple moving average of $4.05 and a two-hundred day simple moving average of $3.09. The stock has a market capitalization of $104.65 million, a P/E ratio of -3.19 and a beta of -1.41. Genelux has a 52 week low of $1.60 and a 52 week high of $6.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of Genelux in the 3rd quarter valued at approximately $59,000. Geode Capital Management LLC raised its holdings in Genelux by 39.7% during the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after buying an additional 89,854 shares during the period. Apollon Wealth Management LLC lifted its position in Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock worth $40,000 after buying an additional 2,857 shares during the last quarter. D.A. Davidson & CO. purchased a new position in Genelux during the fourth quarter worth $51,000. Finally, LifeSteps Financial Inc. boosted its stake in Genelux by 11.1% during the fourth quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after buying an additional 8,715 shares during the period. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.